Safety and efficacy of steroid withdrawal two days after kidney transplantation: Analysis of results at three years

Transplantation

Volumn 81, Issue 6, 2006, Pages 832-839

  Anil Kumar, Mysore S ^a,b   Heifets, Michael ^a   Moritz, Michael J ^a   Saeed, Muhammad I ^a   Khan, Shahid M ^a   Fyfe, Billie ^a   Sustento Riodeca, Nedjema ^a   Daniel, Joshua N ^a   Kumar, Aparna ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Kidney transplant; Surveillance biopsy; Two day steroid withdrawal

Indexed keywords

BASILIXIMAB; COTRIMOXAZOLE; CREATININE; CYCLOSPORIN A; INSULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; RAPAMYCIN; THYMOCYTE ANTIBODY; TSUKUBAENOLIDE; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHEST INFECTION; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COURSE EVALUATION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEW ONSET DIABETES MELLITUS; PATIENT MONITORING; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOPSY; CALCINEURIN; DIABETES MELLITUS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 33645638905     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000203558.34739.c6     Document Type: Article

References (22)

1. Starzl TE, Marcchioro TL, Waddel WR. The reversal of rejection in human renal homograft with subsequent development of homograft tolerance. Surg Gynecol Obstet 1963; 117: 385-395.
2. Julian BA, Laskow DA, Dubovsky J, et al. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991; 325: 544-550.
3. Hollander AA, Hene RJ, Hermans J, et al. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 1997; 8(2): 294-301.
4. Hricik DE, Bartucci MR, Moir EJ, et al. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991; 51(2): 374-377.
5. Almawi WY, Hess DA, Chudzik DM, Rieder MJ. Pretreatment with glucocorticoids enhances T-cell effector function: possible implication for immune rebound accompanying glucocortcoid withdrawal. Cell Transplant 1999; 8: 637-647.
6. Kumar MSA, Xiao S-G, Fyfe B, et al. steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based Immunosuppression and protocol biopsies. Clin Transplant 2005; 19: 61-69.
7. Racusen LC, Solez K, Calvin RB, et al. The Banff working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
8. Kumar MSA, Panigrahi D, Dezii CM, et al. Long-term function and survival of elderly donor kidneys transplanted into young adults. Transplantation 1998; 65: 282-285.
9. Grimm PC, Nickerson P, Gough J, et al. Quantitation of allograft fibrosis and chronic allograft nephropathy. Pediatr Transplant 1999; 3: 257-270.
10. Anil Kumar MS, Moritz MJ, Saeed MI, et al. Avoidance of chronic steroid therapy in African American kidney transplant recipients monitored by surveillance biopsy: 1-year results Am J Transplant 2005; 5: 1-10.
11. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004; 27(Suppl 1): S11-S14.
12. Birkeland SA. Steroid-free Immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. Transplantation 1998; 66: 1207-1210.
13. Matas AJ, Kandaswamy R, Humar A, et al. Long-term immunosuppression with out maintenance prednisone after kidney transplantation. Ann Surg 2004; 240: 510-517.
14. Woodle ES, Vincenti F, Lorber MI, et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under Simulect, Tacrolimus and sirolimus. Am J Transplant 2005; 5: 157-166.
15. Vincenti F, Monaco A, Grinyo J, et al. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3: 306-311.
16. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
17. Cosio FG, Grande JP, Larson TS, et al. Kidney allograft tibrosis and atrophy early after living donor transplantation. Am J Transplant 2005; 5: 1130-1136.
18. Neylon JF. Racial differences in renal transplantation after Immunosuppression with Tacrolimus versus cyclosporine. Transplantation 1998; 65: 515-523.
19. Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliterative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 1289-1293.
20. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004; 77: 244-251.
21. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977.
22. Veenstra DL, Best JH, Hornberger J, et al. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am K Kidney Dis 1999; 33: 829.